The diagnosis of hepatocellular carcinoma (HCC) in the early stages is important for successful clinical management. Laminin (Ln)-γ2 expression has been reported in various types of malignant carcinomas. We recently developed a highly sensitive method to measure serum monomeric Ln-γ2 levels using a fully automated chemiluminescent immunoassay (CLIA). Using our CLIA, we evaluated its diagnostic value in sera from patients with chronic liver disease (CLD) and patients with hepatocellular carcinoma (HCC). Serum alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP) were also examined in these subjects. Median levels of Ln-γ2 were significantly higher in patients with HCC (173.2 pg/mL; range: 39.5-986 pg/mL) compared with patients with CLD (76.7 pg/mL; range: 38.7-215.9 pg/mL) and with healthy volunteers (41.1 pg/mL; range: 10.9-79.0 pg/mL). The optimal cutoff value for Ln-γ2 that allowed us to distinguish between HCC and nonmalignant CLD was 116.6 pg/mL. Elevated Ln-γ2 levels were observed in 0

作者：Hirofumi, Kiyokawa；Hiroshi, Yasuda；Ritsuko, Oikawa；Chiaki, Okuse；Nobuyuki, Matsumoto；Hiroki, Ikeda；Tsunamasa, Watanabe；Hiroyuki, Yamamoto；Fumio, Itoh；Takehito, Otsubo；Toru, Yoshimura；Eisaku, Yoshida；Masatoshi, Nakagawa；Naohiko, Koshikawa；Motoharu, Seiki

来源：Cancer science 2017 年 108卷 7期